In this exclusive interview, Fintan Walton, CEO of PharmaVentures, speaks with Marc Funk, the new CEO of Recipharm. Recipharm is a leading Swedish CDMO, founded in 1995, which has expanded to over 30 sites across 10 countries which are mainly in Europe, but also in...

Can Partnering Conference Cancellations Affect Dealmaking in 2020? We all got used to the partnering conference circuit as a means to introduce the latest developments to potential partners. So now they are all temporarily suspended whilst we...

The Chief Executive of PharmaVentures, a leading global corporate advisory firm in healthcare licensing, M&A and fundraising discusses how the current pandemic of 2020 will define the winners and losers in biopharmaceuticals. https://youtu.be/o81Th7McuHA

What are the most important things to think about when doing a licensing deal with Western big pharma? How do you engage with them and keep the momentum going? Can language become a barrier in doing a deal? How is the Korean biopharmaceutical sector viewed by those of...

Over the past couple of years, we have seen huge growth in the pharma and biotech industries in Asia, and especially in Korea. Historically, the Korean pharmaceutical industry was built on manufacturing and generics capabilities, however, in the past few decades many...

With more than 89 million chronic disease sufferers in the US alone, NetScienctific is focused on fighting chronic diseases on three fronts to create 'next generation healthcare technologies'. Thier healthcare investment strategy is building businesses in digital...